Vertex Pharmaceuticals (VRTX) Expected to Release Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) is anticipated to announce its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of $4.74 per share and revenue of $3.2285 billion for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion. During the same quarter last year, the firm earned $4.06 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. On average, analysts expect Vertex Pharmaceuticals to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $477.36 on Monday. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $533.67. The stock’s 50 day moving average is $465.77 and its two-hundred day moving average is $459.87. The firm has a market capitalization of $121.15 billion, a PE ratio of 28.31, a P/E/G ratio of 2.15 and a beta of 0.29.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Sangeeta N. Bhatia sold 318 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the sale, the director owned 4,924 shares in the company, valued at $2,086,446.52. This represents a 6.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president directly owned 20,729 shares of the company’s stock, valued at $8,810,239.58. The trade was a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 18,874 shares of company stock worth $8,707,966. 0.20% of the stock is currently owned by company insiders.

Institutional Trading of Vertex Pharmaceuticals

Large investors have recently bought and sold shares of the company. Williams Jones Wealth Management LLC. boosted its position in shares of Vertex Pharmaceuticals by 1.9% in the 4th quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock worth $524,000 after buying an additional 21 shares in the last quarter. Financial Engines Advisors L.L.C. grew its stake in Vertex Pharmaceuticals by 4.0% in the 4th quarter. Financial Engines Advisors L.L.C. now owns 653 shares of the pharmaceutical company’s stock valued at $296,000 after acquiring an additional 25 shares during the last quarter. CYBER HORNET ETFs LLC increased its holdings in Vertex Pharmaceuticals by 4.0% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 695 shares of the pharmaceutical company’s stock valued at $272,000 after acquiring an additional 27 shares in the last quarter. PGIM Custom Harvest LLC increased its holdings in Vertex Pharmaceuticals by 2.3% during the 3rd quarter. PGIM Custom Harvest LLC now owns 1,248 shares of the pharmaceutical company’s stock valued at $489,000 after acquiring an additional 28 shares in the last quarter. Finally, ICW Investment Advisors LLC raised its position in Vertex Pharmaceuticals by 5.0% during the second quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock worth $269,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Morgan Stanley increased their target price on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Truist Financial upped their price objective on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Canaccord Genuity Group cut their price objective on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research report on Tuesday, May 5th. Finally, UBS Group raised their target price on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a report on Monday, July 13th. Twenty-two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $559.61.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.